tiprankstipranks

Gaush Meditech Expands Product Portfolio with NMPA Approval for ANTERION

Story Highlights
Gaush Meditech Expands Product Portfolio with NMPA Approval for ANTERION

Gaush Meditech Ltd. ( (HK:2407) ) has provided an update.

Gaush Meditech Ltd announced that its subsidiary, Global Vision Corporation, has successfully obtained the NMPA medical device registration certificate for ANTERION, a multimodal imaging diagnostic platform developed by its partner, Heiderberg Engineering GmbH. This platform, which integrates advanced technologies such as SS-OCT, eye-tracking, and ray-tracing, is designed to enhance diagnostic and treatment efficiency in ophthalmic sub-specialties. The approval enriches Gaush Meditech’s product portfolio, strengthening its position in the high-end medical device market and potentially improving clinical workflows and patient outcomes.

More about Gaush Meditech Ltd.

Gaush Meditech Ltd, incorporated in the Cayman Islands, operates in the medical technology industry, focusing on high-end surgical and diagnostic products. The company, along with its subsidiaries, aims to deliver advanced medical solutions to its customers and patients.

YTD Price Performance: -39.06%

Average Trading Volume: 512,931

Technical Sentiment Consensus Rating: Buy

Current Market Cap: HK$931.7M

For a thorough assessment of 2407 stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App